This study assessed the epidemiological and microbiological invasive pneumococcal disease (IPD) changes that occurred before and after the emergence of COVID-19 in Italy. All IPD cases reported through the nationwide surveillance system during 2018–2023 were included. IPD incidence and serotype distributions were analyzed by age group. IPD incidence in 2020–2021 declined in all age groups compared with 2018–2019, especially in children less than 2 years of age and elderly people aged > 64 years. A resurgence of IPD cases was observed from late 2022 onwards, with values in children exceeding those seen before the pandemic. The post COVID-19 increase in children was mainly driven by some PCV13 serotypes, such as 3, 19A, and 19F, but also non-vaccine serotypes, including 10A, 8, and 24F, while in the elderly population, a predominance of serotypes 3 and 8 was observed. In conclusion, a steep drop in IPD incidence was observed during the peak of the COVID-19 pandemic, followed by a subsequent upsurge of cases, especially in children. Continuous national surveillance is necessary to monitor the dynamics and evolution of IPD and the impact of new higher-valency vaccines in Italy over the next few years.
Background: Methicillin-resistant Staphylococcus aureus (MRSA) poses a major challenge in clinical settings due to limited susceptibility to conventional antibiotics. Ozone (O3), a naturally occurring molecule composed of three oxygen atoms, exhibits strong antimicrobial properties against a wide spectrum of microorganisms, including both Gram-positive and Gram-negative bacteria. The antibacterial efficacy of O3 against pathogenic bacteria has been demonstrated both in vivo and in vitro, although the mechanisms of action remain poorly understood. Notably, O3 has proven effective against MRSA, underscoring the potential of O3 as a valuable adjunctive therapy for managing resistant bacterial infections. Aims: This study aimed to confirm the antibacterial effects of oxygen–O3 (O2–O3) therapy on MRSA strains and to investigate the associated immunomodulatory and antioxidant properties in human peripheral blood mononuclear cells (PBMCs) treated in vitro with MRSA. Methods: PBMCs from healthy donors were initially exposed to heat-killed or O3-treated MRSA strains at 37 °C for 2 hours, then treated with 40 μg/mL O3 for an additional 24 hours to simulate O3 therapy. Subsequently, cytokine release, antioxidant and pro-oxidant gene expression, reactive oxygen species production, and redox-related biomarker levels were assessed. Results: Our findings demonstrated that O3, at various concentrations (20–60 μg/mL) within the therapeutic range (20–80 μg/mL), exerts a potent antibacterial effect against MRSA, resulting in complete loss of bacterial colonies, in the absence of antioxidants in the medium. Using a multidisciplinary approach encompassing biochemical, molecular, and cell biology techniques, we observed that O3 exerts immunomodulatory and antioxidant effects on PBMCs exposed to O3 and stimulated with MRSA as early as 1 hour after stimulation, with these effects persisting for up to 48–72 hours, regardless of whether the bacteria were inactivated by O3 or heat. Conclusions: We successfully demonstrated that O3 exerts an early antibacterial effect, followed by antioxidant activity and immunomodulatory properties, as confirmed by multiple integrated analyses. These findings highlight the potential of O3 as a promising strategy to combat antibiotic resistance and support therapeutic protocols.
TSthe Italian CRE25 survey working group for Klebsiella pneumoniae ST6668
the Italian CRE25 survey working group for Klebsiella pneumoniae ST6668
+17
Preliminary analysis of genomic surveillance data from the European Antimicrobial Resistance Gene Surveillance Network detected the spread of the emerging carbapenemase-producing Klebsiella pneumoniae sequence type ST6668 in 19 NUTS-2 regions in Italy (8 regions) and five other European Union (EU) countries (11 regions) in the period April 2022 to August 2026. These findings demonstrate the vulnerability of EU healthcare facilities to the rapid spread of K. pneumoniae high-risk lineages from uncontrolled local outbreaks via national and cross-border patient mobility.
In the European region, diphtheria is now rarely suspected in patients presenting with upper respiratory tract symptoms. Corynebacterium ulcerans is the underestimated zoonosis that is replacing C. diphtheria infections in industrialized countries, but extensive human and animal prevalence studies are lacking. The range of hosts that can act as reservoirs for C. ulcerans is very broad, companion pets currently being the main source of human infection. We report a case of macrolide-resistant C. ulcerans infection with no apparent zoonotic transmission and outline the efforts required for the public and zooprophylactic management of these cases. We describe the main critical issues to be addressed to comprehensively tackle this zoonosis in the future.